<DOC>
	<DOCNO>NCT01800487</DOCNO>
	<brief_summary>Hepatitis one common adverse effect anti-tuberculosis . Silymarin show efficacy decrease serum alanine transaminase enzyme animal model recent study . No confirm efficacy perform human . A prospective , double-blind , placebo-controlled trial carry accord Good Clinical Practice Guideline . This study define efficacy silymarin prevent hepatotoxicity anti-tuberculosis drug . Informed consent obtain prior study . New patient diagnosed tuberculosis enrol . Patients liver disease , current alcohol drinking 20 g/day , regular use herbal potential hepatotoxic drug exclude . Patients treated standard regimen four anti-tuberculosis therapy . They randomize receive either placebo silymarin ( 140 mg ) thrice daily . Liver function test ( LFT ) clinical change assess 2- 4-week initiation treatment . DILI anti-tuberculosis drug ( 'atb-DILI ' ) define : ) rise alanine aminotransferase ( ALT ) 2 time normal upper limit , ii ) elevation total bilirubin 2 mg/dl without ALT elevation . The study endpoint level ALT week 4 number patient develop atb-DILI . Statistical analysis use compare difference ALT number atb-DILI</brief_summary>
	<brief_title>The Efficacy Silymarin Prevention Hepatotoxicity From Antituberculosis Drugs</brief_title>
	<detailed_description>- Prevention antituberculosis-related drug induce liver injury silymarin investigate .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<mesh_term>Silymarin</mesh_term>
	<mesh_term>Antitubercular Agents</mesh_term>
	<criteria>tuberculosis case treat isoniazid , rifampicin , ethambutol pyrazinamide know liver disease ( HBV , HCV ) , HIV infection normal ALT level enrollment refuse participate</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Drug-induced liver injury</keyword>
	<keyword>Tuberculosis</keyword>
	<keyword>Silymarin</keyword>
</DOC>